-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) Epidemiology Analysis and Forecast to 2032
Non-Small Cell Lung Cancer (NSCLC) Report Overview In the 8MM, there were 1,097,467 diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) in 2022. The diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) will register an AGR of more than 2% during 2022-2032. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, NSCLC can begin anywhere in the lungs when the healthy cells that make up the lining of the lungs change and grow out...
-
Product Insights
Lung Adenocarcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Lung Adenocarcinoma - Drugs In Development, 2023’, provides an overview of the Lung Adenocarcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lung Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Squamous Non-Small Cell Lung Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Squamous Non-Small Cell Lung Cancer - Drugs In Development, 2023’, provides an overview of the Squamous Non-Small Cell Lung Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Squamous Non-Small Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Non-Small Cell Lung Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Non-Small Cell Lung Carcinoma - Drugs In Development, 2023’, provides an overview of the Non-Small Cell Lung Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Squamous Non-Small Cell Lung Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Squamous Non-Small Cell Lung Carcinoma - Drugs In Development, 2023’, provides an overview of the Squamous Non-Small Cell Lung Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Squamous Non-Small Cell Lung Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Thematic Analysis
Digital Marketing Trends in Non-small Cell Lung Cancer
Digital Marketing Trends in Non-small Cell Cancer Report Overview Merck’s Keytruda.com achieved the highest total traffic across Non-small Cell Lung Cancer (NSCLC) patient sites in the US from October 2022 to September 2023. This was followed by BMS's Opdivo.com and AstraZeneca's Imfinzi.com. Keytruda.com was also supported by the most paid search engine optimization (SEO) at over 7,600 keywords, closely followed by Enhertu.com and Opdivo.com. Overall, the highest proportion of traffic to top branded patient NSCLC websites originated from direct and organic sources. The Digital...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Non-Small Cell Lung Cancer Market Report Overview The non-small cell lung cancer (NSCLC) market size for the 15 markets (15M) was $30.7 billion in 2021. This included both Cell & gene therapies (CGTs) and established/traditional therapies. Cell therapies, consisting mostly of tumor-infiltrating lymphocytes (TILs) and CAR-T cells, are the most-abundant modality type in the NSCLC CGT pipeline but fall far behind traditional therapies such as monoclonal antibodies and small molecules. The non-small cell lung cancer market research report includes an...
-
Product Insights
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in the later stages of the disease. The signs and symptoms include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody...
-
Sector Analysis
Non-Small Cell Lung Cancer – Global Drug Forecast and Market Analysis to 2029
Non-small cell lung cancer (NSCLC) is currently the most common cancer in the world and is the leading cause of cancer mortality in men and women. Of total lung cancer incident cases, approximately 85% are the NSCLC subtype. NSCLC patients are usually diagnosed in the later stages of the disease, resulting in a poor prognosis. Since the last global market forecast (2015–2025), there have been significant changes in the treatment of patients with advanced disease, particularly in the metastatic setting....